Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Invested Capital (2019 - 2023)

Denali Therapeutics (DNLI) has disclosed Return on Invested Capital for 5 consecutive years, with 0.18% as the latest value for Q4 2023.

  • Quarterly Return on Invested Capital rose 18.0% to 0.18% in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 0.18% through Dec 2023, up 18.0% year-over-year, with the annual reading at 0.49% for FY2025, 6.0% down from the prior year.
  • Return on Invested Capital for Q4 2023 was 0.18% at Denali Therapeutics, down from 0.15% in the prior quarter.
  • The five-year high for Return on Invested Capital was 0.06% in Q4 2020, with the low at 0.49% in Q1 2020.
  • Average Return on Invested Capital over 5 years is 0.2%, with a median of 0.18% recorded in 2019.
  • The sharpest move saw Return on Invested Capital skyrocketed 53bps in 2021, then tumbled -39bps in 2022.
  • Over 5 years, Return on Invested Capital stood at 0.18% in 2019, then skyrocketed by 135bps to 0.06% in 2020, then plummeted by -590bps to 0.3% in 2021, then decreased by -22bps to 0.37% in 2022, then surged by 50bps to 0.18% in 2023.
  • According to Business Quant data, Return on Invested Capital over the past three periods came in at 0.18%, 0.15%, and 0.15% for Q4 2023, Q3 2023, and Q2 2023 respectively.